Esperion Therapeutics | ESPR - Interest Income


Esperion Therapeutics reported $-0.15 in Interest Income for its fiscal quarter ending in September of 2024.





Interest Income Change Date
AbbVie USD 72M 10M Sep/2025
Alnylam Pharmaceuticals USD 28.68M 1.19M Sep/2025
Amarin USD 3.37M 3.37M Dec/2024
Biogen USD 31.6M 700K Sep/2025
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
CSL USD 18M 1000K Dec/2024
Cytokinetics USD 10.25M 2.75M Sep/2025
Daiichi Sankyo JPY 9.96B 230M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Geron USD 4.26M 392K Sep/2025
Heron Therapeutics USD 433K 277K Dec/2021
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Merck USD 96M 27M Sep/2025
Moderna USD 73M 8M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 0.62 156M Sep/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sanofi EUR 114M 38M Sep/2025
Sarepta Therapeutics USD 8.38M 1.24M Sep/2025
United Therapeutics USD 46.4M 4.9M Sep/2025